A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

AIMS/HYPOTHESIS: Numerous clinical studies have investigated the anti-CD3ɛ monoclonal antibody otelixizumab in individuals with type 1 diabetes, but limited progress has been made in identifying the optimal clinical dose with acceptable tolerability and safety. The aim of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Keymeulen, Bart, van Maurik, André, Inman, Dave, Oliveira, João, McLaughlin, Rene, Gittelman, Rachel M., Roep, Bart O., Gillard, Pieter, Hilbrands, Robert, Gorus, Frans, Mathieu, Chantal, Van de Velde, Ursule, Wisniacki, Nicolas, Napolitano, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801303/
https://www.ncbi.nlm.nih.gov/pubmed/33145642
http://dx.doi.org/10.1007/s00125-020-05317-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801303/
https://www.ncbi.nlm.nih.gov/pubmed/33145642
http://dx.doi.org/10.1007/s00125-020-05317-y

Ejemplares similares